12126-59-9C[C@]12CC[C@H]3C(=CCc4cc(OS(=O)(=O)[O-])ccc43)[C@@H]1CCC2=O.[Na+]QTTMOCOWZLSYSV-QWAPEVOJSA-MEquilin sodium sulfate is a steroid sulfate. It is functionally related to an equilin.
12126-59-9、16680-47-0FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
When heated to decomposition it emits toxic fumes of /Sodium oxide/. /Equigyne/
When heated to decomposition it emits acrid smoke and irritating fumes. /Premarin/
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H350 (69.6%): May cause cancer [Danger Carcinogenicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 56 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including estrogens, conjugated, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
National Toxicology Program. Eleventh Report on Carcinogens (2005). The Report on Carcinogens is an informational scientific and public health document that identifies and discusses substances (including agents, mixtures, or exposure circumstances) that may pose a carcinogenic hazard to human health. Estrogens, Steroidal are listed as known to be human carcinogens. /Estrogens, Steroidal/[Available from, as of July 31, 2009: http://ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s084ster.pdf]
All estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as Hormone Replacement Therapy (HRT).
The principal pharmacologic effects of conjugated estrogens are similar to those of other natural and synthetic estrogens.
Estrogens have an important role in the reproductive, skeletal, cardiovascular, and central nervous systems in women, and act principally by regulating gene expression. Biologic response is initiated when estrogen binds to a ligand-binding domain of the estrogen receptor resulting in a conformational change that leads to gene transcription through specific estrogen response elements (ERE) of target gene promoters; subsequent activation or repression of the target gene is mediated through 2 distinct transactivation domains (ie, AF-1 and AF-2) of the receptor. The estrogen receptor also mediates gene transcription using different response elements (ie, AP-1) and other signal pathways. Recent advances in the molecular pharmacology of estrogen and estrogen receptors have resulted in the development of selective estrogen receptor modulators (eg, clomiphene, raloxifene, tamoxifen, toremifene), agents that bind and activate the estrogen receptor but that exhibit tissue-specific effects distinct from estrogen. Tissue-specific estrogen-agonist or -antagonist activity of these drugs appears to be related to structural differences in their estrogen receptor complex (eg, specifically the surface topography of AF-2 for raloxifene) compared with the estrogen (estradiol)-estrogen receptor complex. A second estrogen receptor also has been identified, and existence of at least 2 estrogen receptors (ER-alpha, ER-beta) may contribute to the tissue-specific activity of selective modulators. While the role of the estrogen receptor in bone, cardiovascular tissue, and the CNS continues to be studied, emerging evidence indicates that the mechanism of action of estrogen receptors in these tissues differs from the manner in which estrogen receptors function in reproductive tissue. /Estrogen General Statement/
DTXSID00872961CHEMBL1201466CHEBI:32143Commercially available conjugated estrogens USP tablets, synthetic conjugated estrogens A tablets, synthetic conjugated estrogens B tablets, and conjugated estrogens USP vaginal cream should be stored at controlled room temperature (20-25 °C). Conjugated estrogens USP powder for injection should be stored at a temperature of 2-8 °C prior to reconstitution. Following reconstitution, solutions of the drug should be used immediately.
SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.
SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
Metabolism of estrogen is mediated in part by cytochrome P-450 (CYP) isoenzyme 3A4, and the possibility exists that drugs that induce or inhibit this isoenzyme may affect plasma estrogen concentrations. Concomitant use of estrogens with drugs that induce CYP3A4 (eg, carbamazepine, phenobarbital, rifampin, St. John's wort [Hypericum perforatum]) may result in decreased plasma concentrations of estrogen, resulting in decreased therapeutic effects and/or changes in uterine bleeding profile. /Estrogen General Statement/
Concomitant use of estrogen with drugs or foods that inhibit CYP3A4 (eg, clarithromycin, erythromycin, grapefruit juice, itraconazole, ketoconazole) may result in increased plasma concentrations of estrogens and an increase in the incidence of adverse effects. /Estrogen General Statement/
Rifampin reportedly decreases estrogenic activity during concomitant use with estrogens. This effect has been attributed to enhanced metabolism of estrogen, presumably by induction of hepatic microsomal enzymes. /Estrogen General Statement/
Estrogens have been reported to enhance the anti-inflammatory effect of hydrocortisone in patients with chronic inflammatory skin diseases. It has been suggested that estrogens may decrease the hepatic metabolism of corticosteroids and/or alter serum corticosteroid protein binding. Patients receiving concomitant estrogen and corticosteroid therapy should be observed for signs of excessive corticosteroid effects... /Estrogen General Statement/
While early formulations of OCCs were associated with frequent serum enzyme elevations, current formulations and hormonal replacement therapy have not been linked to ALT or alkaline phosphatase elevations at rates any higher than occur with placebo. Estrogens and OCCs can cause mild inhibition of bilirubin excretion, leading to jaundice in patients with inherited forms of bilirubin metabolism such as the Dubin Johnson syndrome. More importantly, estrogens and OCCs can induce a clinically apparent cholestatic liver injury which typically arises during the first few cycles of therapy, and rarely after the six months (Case 1). The onset is typically insidious with fatigue and pruritus, followed by nausea, dark urine and jaundice. Serum enzyme elevations are usually mixed or cholestatic, although very early during the injury, ALT levels can be markedly elevated (5- to 20-fold). The characteristic pattern, however, is bland intrahepatic cholestasis and liver biopsy shows little inflammation or hepatocyte necrosis. Resolution may be delayed (Case 2), but estrogens have not been definitely linked to chronic injury, vanishing bile duct syndrome or acute liver failure. Women with OCC induced cholestasis often have a history of idiopathic cholestasis of pregnancy and there is likely a genetic component, most commonly with variants in the bile salt export pump (BSEP, ABC B11). Estrogens and particularly combinations of estrogens and progestins have been linked to episodes of marked serum aminotransferase elevations without symptoms, jaundice or cholestasis. The abnormalities resolve quickly with stopping the hormonal treatment. This syndrome may be more frequent with progestins than with estrogens alone.
TERRESTRIAL FATE: Based on a classification scheme(1), Koc values ranging from 420(2) to 18,000(3) indicate that estrogenic substances are expected to have moderate to no mobility in soil(SRC). Volatilization of estrogenic substance from moist soil surfaces is not expected to be an important fate process(SRC) given estimated Henry's Law constants of >2.0X10-9 atm-cu m/mole(SRC), using a fragment constant estimation method(4). Estrogenic substances are not expected to volatilize from dry soil surfaces(SRC) based upon estimated vapor pressures of >1.0X10-9 mm Hg at 25 °C(SRC), determined from a fragment constant method(5). Bacteria present in wastewater are capable of completely biodegrading natural estrogenic compounds(2). The synthetic estrogen ethinylestradiol has been classified as not readily biodegradable using a sewage treatment plant study(6).
AQUATIC FATE: Based on a classification scheme(1), Koc values ranging from 420(2) to 18,000(3) indicate that estrogenic substances are expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(SRC) based upon estimated Henry's Law constants of >2.0X10-11 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(5), estimated BCF values of 19-110(SRC), from measured log Kow values(6) and a regression-derived equation(7), suggests the potential for bioconcentration in aquatic organisms is low to high, provided the compounds are not metabolized by organisms(SRC). Bacteria present in wastewater are capable of completely biodegrading natural estrogenic compounds(2). The synthetic estrogen ethinylestradiol has been classified as not readily biodegradable using a sewage treatment plant study(8).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), estrogenic substances, which have estimated vapor pressures of >1.0X10-9mm Hg at 25 °C(SRC), determined from a fragment constant method(2), are expected to exist solely in the particulate phase. Particulate-phase estrogenic substances may be removed from the air by wet or dry deposition(SRC). Estriol absorbs light at wavelengths 280 nm(3). Estrone irradiated with a xenon arc lamp exhibited a photodegradation half-life of 2-3 hours in river water and 4.7 hours in air-saturated purified water(4). Therefore, estrogenic substances may be susceptible to direct photolysis by sunlight(SRC).
Average phytoestrogen levels in foods purchased in Cambridgeshire, Great Britain (detection limit = 1.5 ug/100 g dry weight)(1).
Average phytoestrogen levels in foods purchased in Cambridgeshire, Great Britain (detection limit = 1.5 ug/100 g dry weight)(1).
Average phytoestrogen levels in foods purchased in Cambridgeshire, Great Britain (detection limit = 1.5 ug/100 g dry weight)(1).
Average phytoestrogen levels in foods purchased in Cambridgeshire, Great Britain (detection limit = 1.5 ug/100 g dry weight)(1).
For more Food Survey Values (Complete) data for ESTROGENIC SUBSTANCES, CONJUGATED (7 total), please visit the HSDB record page.
Phytoestrogens, secondary plant metabolites which are structurally or functionally similar to 17beta-estradiol(1), have been identified in plants(2). Source plants include pomegranate, apples, and corn species in the case of estrone(3).
Average phytoestrogen levels in foods purchased in Cambridgeshire, Great Britain (detection limit = 1.5 ug/100 g dry weight)(1).
The literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent. Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2). Effluents have been shown to contain several compounds with estrogenic properties. These include natural estrogens and synthetic estrogens widely used in birth-control pills. Women are the primary sources of these estrogenic compounds and during sewage treatment, these conjugates are transformed into the parent and biologically-active compounds(3).
Daily Estrogenic Compounds Excretion by Humans, 2000(1).
Estradiol equivalent concentrations in influents and effluents of sewage treatment plants located along the Yeongsan and Seomijin Rivers in Korea were investigated. The treatment processes of Korean STPs were sufficient to reduce estrogenic activity of municipal wastewater. Surface water samples from Laos, Cambodia, Vietnam, China, Indonesia, Thailand and Malaysia showed higher estradiol equivalent concentrations in comparison to that reported in European countries, America, and Japan(1). Land application of animal manures results in endocrine-disrupting compounds such as estrogenic compounds being released to the environment, posing a threat to aquatic and wildlife species. Surface runoff of estrogenic compounds can be much lower from soils amended with pelletized poultry litter than the raw form of litter(2).
Estrogenic compounds present in animal manure(1).
The Koc of estrogenic substances generally fall into the range of 420(1) to 18,000(2). According to a classification scheme(3), this Koc range suggests that estrogenic substances are expected to have moderate to no mobility in soil. Natural estrogens are mainly removed from the aqueous phase by adsorption onto solids such as sludge in wastewater or soil in cases of land application(1). In soils with a long history of treatment with manure, biosolids, or wastewater, sorption of estrogenic substances may be dependent on soil organic carbon content(4).
Estrogens are a group of naturally occurring steroid sex hormones which are characterized by their ability to induce estrus in the female mammal(1). Estrogenic activity is not restricted to the estrogenic sex hormones. Certain plant constituents, bituminous components of the Seefeld oil shale, easily synthesized stilbene derivatives, and their dihydro compounds have estrogenic properties(2).
/HUMAN EXPOSURE STUDIES/ Postmenopausal conjugated equine estrogens (CEE) therapies increase the risk of cognitive impairment in women aged 65 years or older and are associated with smaller regional brain volumes; however, the link between these two phenomena has not been established. Standardized magnetic resonance imaging was performed on 1,403 women, 1-4 years after they had participated in randomized placebo-controlled clinical trials of CEE-based therapies. Women included in this report were aged 65-80 years and free of dementia and mild cognitive impairment (MCI) when originally enrolled in the trials, which lasted an average of 4-6 years and were conducted at 14 academic U.S. medical centers. The associations that regional brain volumes and ischemic lesion volumes had with the development of cognitive impairment (ie, dementia or MCI) were contrasted between treatment groups using analyses of covariance. Fifty-three women developed MCI or probable dementia during follow-up. Among women who had been prescribed CEE-based therapies, cognitive impairment was associated with relatively smaller hippocampal (p = 0.0002) and total brain volumes (p = 0.03). Qualitatively, these associations appeared to be independent of their level of pretreatment cognitive function. Among women who had been prescribed placebo, these relationships were not evident; instead, cognitive impairment was associated with greater ischemic lesion volume in the frontal lobe (p = 0.007) and overall (p = 0.02). A mechanism by which CEE-based postmenopausal hormone therapy induces cognitive impairment appears to be through increased brain atrophy.
/HUMAN EXPOSURE STUDIES/ ... A rise in cholesterol saturation of hepatic bile was observed after giving conjugated equine estrogens (0.5 mg/kg) to 7 fasting patients with indwelling T-tubes. Liver function tests were normal and bile culture was negative. One mL of hepatic bile was collected aft er 6, 12, and 24 hours for lipid determinations. The administration of estrogens promptly produced lithogenic hepatic bile. The effect was transient with the lithogenic index returning to normal at 24 hours. 3 days previous to this investigation hepatic bile had been normal. ...
/SIGNS AND SYMPTOMS/ Acute overdosage of large doses of oral contraceptives in children reportedly produces almost no toxicity except nausea and vomiting. Acute overdosage of estrogens may cause nausea, and withdrawal bleeding may occur in females. /Estrogen General Statement/
/CASE REPORTS/ To report a case of fatal pulmonary embolism associated with the use of iv estrogen therapy for menometrorrhagia. A 52-year-old woman with fibroid uterus treated with GnRH analogues with add-back therapy who presented with excessive vaginal bleeding. Intravenous conjugated estrogens were administered for a total of six doses. A fatal thromboembolic event /occurred/. The day after iv conjugated estrogens were administered, the patient had only scant vaginal bleeding, but she experienced the sudden onset of respiratory distress, became comatose, and subsequently had ventricular fibrillation leading to asystole. All resuscitative efforts failed. Postmortem examination revealed bilateral pulmonary artery thromboembolism (saddle embolus). Intravenous conjugated estrogen therapy may be complicated by fatal thromboembolic events. This potential adverse effect must be considered in the use of such therapy for severe menometrorrhagia, especially when treating a patient at increased risk.
A correlation has been established between estrogenic compounds in effluents from sewage treatment plants and the occurrence of vitellogenin (a female specific egg-yolk precursor) production in males(1) and intersex in fish living in the receiving environment(2). Grey mullet were collected from Ansan, Jeju, Yeoso, Tongyeong, and Busan in Kirea and Nagasaki, Omuta, and Fukuoka in Japan. Contamination by environmental estrogens was evident as indicated by vitellogenin levels in serum greater that 1.0 ug/mL(3). Samples downstream from 2 sewage treatment plants as well as from bleached craft mill industry, 5 rivers in the Walloon region (southern Belgium). Results indicate significant estrogenicity of effluents from STP and BKME; however estradiol equivalents estimated into rivers were probably too low to impact the wild population. Vitellogenin over-expression was found for male fish presenting a feminization of the reproductive tract captured downstream from the STP station in Wegnez in the Vesdre River. Intersexuality , another indicator of the estrogencity impact in fish, was observed in every site(4).
Average phytoestrogen levels in foods purchased in Cambridgeshire, Great Britain (detection limit = 1.5 ug/100 g dry weight)(1).
Since 1930 synthesized steroid hormone analogues have been developed with improved therapeutic properties for the control of pituitary function, for substitution therapy in deficiency syndromes such as hypogonadism or after the menopause, and particularly for the control of ovulation (contraceptive steroids). Estrogenic hormones are used in substitution therapy to control estrogen deficiency caused by ovarian hypofunction, castration, or menopause. They are also used in suppression therapy to suppress gonadotropin-induced ovulation and the endogenous production of estrogens. Because of the latter, estrogens are used together with gestagens as combination contraceptive agents(1). These applications may result in their release to the environment through various waste streams(SRC).
The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including estrogens, conjugated, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
Intracellular cytosol-binding proteins for estrogens have been identified in estrogen-responsive tissues including the female genital organs, breasts, pituitary, and hypothalamus. The estrogen-binding protein complex (ie, cytosol-binding protein and estrogen) distributes into the cell nucleus where it stimulates DNA, RNA, and protein synthesis. The presence of these receptor proteins is responsible for the palliative response to estrogen therapy in women with metastatic carcinoma of the breast. /Estrogen General Statement/
Estrogens have generally favorable effects on blood cholesterol and phospholipid concentrations. Estrogens reduce LDL-cholesterol and increase HDL-cholesterol concentrations in a dose-related manner. The decrease in LDL-cholesterol concentrations associated with estrogen therapy appears to result from increased LDL catabolism, while the increase in triglyceride concentrations is caused by increased production of large, triglyceride-rich, very-low-density lipoproteins (VLDLs); changes in serum HDL-cholesterol concentrations appear to result principally from an increase in the cholesterol and apolipoprotein A-1 content of HDL2- and a slight increase in HDL3-cholesterol. /Estrogen General Statement/
For more Mechanism of Action (Complete) data for ESTROGENIC SUBSTANCES, CONJUGATED (7 total), please visit the HSDB record page.
The half life of baseline-corrected estrone and equilin was found to be 10.6 hr and 9.7 hr, respectively.
The mean (SD) apparent terminal elimination half-life of conjugated estrone is 14 (+/- 6) hours and conjugated equilin is 11 (+/- 6) hours. /Synthetic conjugated estrogens, B/
Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women a significant portion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4).
Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women a significant portion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.
The steroidal estrogens are metabolized principally in the liver, although the kidneys, gonads, and muscle tissues may be involved to some extent. The steroids and their metabolites are conjugated at the hydroxyl group of the C 3 position with sulfuric or glucuronic acid; these conjugates may undergo further metabolic change. Conjugation increases water solubility and facilitates excretion in urine. Large amounts of free estrogens are also distributed into the bile, reabsorbed from the GI tract, and recirculated through the liver where further degradation occurs. /Estrogen General Statement/
The metabolic disposition of estrogens includes oxidative metabolism (largely hydroxylation) and conjugative metabolism by glucuronidation, sulfonation and/or O-methylation. Estradiol is converted to estrone by a 17beta-hydroxysteroid dehydrogenase; the estrone produced is further metabolized to 16alpha-hydroxyoestrone and then to estriol. Hydroxylation of estradiol at the 2 position is a major metabolic pathway in the liver. There are large inter-individual differences in estradiol 2-hydroxylation in human liver samples, which may be reflected by differences in estrogenic action. 4-Hydroxylation of estradiol to a catechol is a minor pathway (usually < 15% of 2-hydroxylation) in the liver.
Estrone sulfate is the estrogen found at the highest concentration in plasma and seems to constitute a storage form for circulating estrogens. Estrone sulfate can be hydrolysed to estrone by arylsulfatases, which are widely distributed in human tissues.
Conjugated equine estrogens are hydrolysed to their active form in the gastrointestinal tract and also undergo considerable hepatic metabolism before entering the bloodstream in an active form. Most sulfate esters are hydrolysed to free or unconjugated estrogen by enzymes in the lower gut; the free estrogen is absorbed by intestinal tissue, where it can be reconjugated with sulfate. Therefore, the estrogen sulfate found in the bloodstream is not the same sulfate that was administered. The rate of dissolution is important because it influences where the active ingredients of the product are released in the gastrointestinal tract, a factor which may affect the amounts of the estrogen that are activated and the patterns of active and inactive metabolites. Equilin and equilenin are interconverted to 17beta-dihydroequilin and 17beta-dihydroequilenin and correspond to the interrelation between estrone and estradiol. As in the case of natural estrogen in women, there is an equilibrium between equilin, equilenin and their metabolites and the respective sulfates.
Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
Synthetic conjugated estrogens, A are soluble in water and are well absorbed from the gastrointestinal tract after release from the drug formulation. The Cenestin tablet releases the synthetic conjugated estrogens, A slowly over a period of several hours
Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.
The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs.
Following oral administration, the natural, unconjugated estrogens are inactivated in the GI tract and liver. Conjugated estrogens and some synthetic derivatives of the natural estrogens may be administered orally. Absorption and metabolism following oral administration of these drugs is rapid and daily doses are usually required. /Estrogen General Statement/
Synthetic conjugated estrogens are soluble in water and are well absorbed from the gastrointestinal tract after release from the drug formulation. The Synthetic conjugated estrogens tablet releases the synthetic conjugated estrogens slowly over a period of several hours.
Estrogens are readily absorbed through the skin and mucous membranes. Depending on the amount of estrogen applied, systemic as well as local effects may occur following topical application. /Estrogen General Statement/
Medicine, biochemical research, oral contraceptives /Estrogen/
MEDICATION
Complex mixture of natural estrogens obtained from equine urine or synthetically from estrone and equilin. Principal components are sodium estrone sulfate and sodium equilin sulfate; also known to contain 17alpha-dihydroequilin, 17alpha-estradiol, and 17beta-dihydroequilin as sodium sulfate conjugates.
Conjugated estrogens tablets, USP for oral administration contains a mixture of conjugated estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains as concomitant components, as sodium sulfate conjugates, 17alpha-dihydroequilin, 17alpha-estradiol, and 17beta-dihydroequilin.
Synthetic conjugated estrogens A tablets contain a blend of nine (9) synthetic estrogenic substances. The estrogenic substances are sodium estrone sulfate, sodium equilin sulfate, sodium 17alpha-dihydroequilin sulfate, sodium 17alpha-estradiol sulfate, sodium 17beta-dihydroequilin sulfate, sodium 17alpha-dihydroequilenin sulfate, sodium 17beta-dihydroequilenin sulfate, sodium equilenin sulfate and sodium 17beta-estradiol sulfate.
Synthetic conjugated estrogens B tablets contain a blend of ten (10) synthetic estrogenic substances. The estrogenic substances are: sodium estrone sulfate, sodium equilin sulfate, sodium 17alpha-dihydroequilin sulfate, sodium 17alpha-estradiol sulfate, sodium 17beta-dihydroequilin sulfate, sodium 17alpha-dihydroequilenin sulfate, sodium 17beta-dihydroequilenin sulfate, sodium equilenin sulfate, sodium 17beta-estradiol sulfate, and sodium delta8,9-dehydroestrone sulfate.
CENESTIN tablets for oral administration, are available in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg strengths of synthetic conjugated estrogens, A. Tablets also contain the following inactive ingredients: ethylcellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, polysorbate 80, pregelatinized starch, titanium dioxide, and triethyl citrate.
For more Formulations/Preparations (Complete) data for ESTROGENIC SUBSTANCES, CONJUGATED (6 total), please visit the HSDB record page.
The term "conjugated estrogens" refers to mixtures of at least eight compounds, including sodium estrone sulfate and sodium equilin sulfate, that are derived wholly or in part from equine urine, are plant-based or are manufactured synthetically from estrone and equilin. Conjugated estrogens contain as concomitant components the sodium sulfate conjugates of 17alpha-dihydroequilin, 17beta-dihydroequilin and 17alpha-estradiol.
Conjugated estrogens (natural) are a mixture that contains the sodium salts of the water soluble sulfate esters of estrone and equilin derived wholly or in part from equine urine or prepared synthetically from estrone and equilin. Conjugated estrogens (natural) also contain conjugated estrogenic substances of types that are excreted by pregnant mares and include delta8,9-dehydroestrone, 17alpha-dihydroequilenin, 17beta-dihydroequilenin, 17alpha-dihydroequilin, 17beta-dihydroequilin, equilenin, 17alpha-estradiol and 17beta-estradiol.
Conjugated estrogens (synthetic) are a mixture of conjugated estrogens that are prepared synthetically from plant sources (i.e. soy (Glycine Max) and yams (Dioscorea Mexicana)). Conjugated estrogens (synthetic) are commercially available as preparations that contain a mixture of nine of the 10 known conjugated estrogenic substances that are present in currently available commercial preparations of conjugated estrogens (natural). However, in contrast to currently available preparations of conjugated estrogens (natural), the conjugated estrogenic substances present in conjugated estrogens (synthetic) are prepared entirely synthetically.
In general, the pharmacological activity of synthetic gonadal steroids is never limited to interaction with a particular type of receptor (i.e., estrogenic, androgenic, progestagenic, glucocorticoid, or mineralocorticoid); instead, the spectrum of biological and pharmacological activities is dose-dependent. For example, some synthetic C-19 steroids have a high progestagenic potency, but frequently retain androgenic effects. The synthetic estrogen 17-ethinyl-estradiol displays high oral absorption due to its low metabolic inactivation and has become a major component of oral contraceptives.
DescriptionConjugated estrogens generally occur as butter-colored powders that are soluble in water. The sodiumequilin sulfate component is unstable to light and air.Piperazine estrone sulfate occurs as a white to yellowishwhite crystalline powder that is slightly soluble in water.Piperazine estrone sulfate melts at 245℃ with decomposition. Conjugated estrogens are naturally occurring substances excreted in the urine of pregnant mares; piperazineestrone sulfate is not known to occur naturally.
UsesConjugated Estrogen is a mixture of estrogen derivatives-mostly estrone and equilin sulfate.
DefinitionChEBI: Equilin sodium sulfate is a steroid sulfate. It is functionally related to an equilin.
For more Human Toxicity Excerpts (Complete) data for ESTROGENIC SUBSTANCES, CONJUGATED (26 total), please visit the HSDB record page.